Senseonics Expands European Eversense Operations via Asset Agreements

An announcement from Senseonics Holdings ( (SENS) ) is now available.

On December 31, 2025, Senseonics entered into a master asset purchase agreement with Ascensia Diabetes Care to acquire assets related to the marketing, sale and distribution of the Eversense CGM product in the U.S., effective January 1, 2026, and to pursue additional asset purchases in several European markets. On March 12, 2026, the parties signed local asset purchase agreements for Italy, Germany, Spain and Sweden, under which Senseonics will acquire Ascensia’s related commercial assets and assume specified liabilities, with closings targeted by June 30, 2026, subject to regulatory and customary conditions, and supported by a transition services agreement aimed at ensuring continuity of logistics, IT, regulatory and operational functions during the handover.

The European local agreements provide for cash payments based on the net book value of the acquired assets and assumed liabilities in each country, aligning consideration with the underlying business transferred. To preserve and smoothly transition the Eversense operations in these markets, Ascensia will provide Senseonics with transition services in areas including logistics, payment and collections, tender contract performance, IT and systems migration, employee and operations support, and regulatory compliance generally through June 30, 2026, in return for agreed costs and service fees.

The most recent analyst rating on (SENS) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Spark’s Take on SENS Stock

According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.

The score is held back primarily by weak financial performance—large recurring losses and persistent negative free cash flow—despite improving revenue growth and margin trends. Technical indicators are constructive in the near term, and the earnings call includes strong growth guidance, but elevated planned 2026 spending and cash utilization meaningfully increase execution and funding risk.

To see Spark’s full report on SENS stock, click here.

More about Senseonics Holdings

Senseonics Holdings is a medical technology company focused on diabetes management, developing and commercializing the Eversense implantable continuous glucose monitoring (CGM) system. The company’s primary products support long-term glucose monitoring for people with diabetes, with a market focus that includes the United States and key European territories such as Italy, Germany, Spain and Sweden.

Average Trading Volume: 509,207

Technical Sentiment Signal: Strong Sell

Current Market Cap: $243.9M

For an in-depth examination of SENS stock, go to TipRanks’ Overview page.